key: cord-0839394-rorstg15
authors: Le Borgne, Pierrick; Solis, Morgane; Severac, François; Merdji, Hamid; Ruch, Yvon; Alamé Intern, Karine; Bayle, Eric; Hansmann, Yves; Bilbault, Pascal; Fafi‐Kremer, Samira; Meziani, Ferhat
title: SARS‐CoV‐2 viral load in nasopharyngeal swabs in the emergency department does not predict COVID‐19 severity and mortality
date: 2021-02-05
journal: Acad Emerg Med
DOI: 10.1111/acem.14217
sha: 5752cf7583898becc21a86c3f29727c273617a23
doc_id: 839394
cord_uid: rorstg15

INTRODUCTION: The ongoing COVID‐19 pandemic has led to devastating repercussions on health care systems worldwide. This viral infection has a broad clinical spectrum (ranging from influenza‐like disease, viral pneumonia, and hypoxemia to acute respiratory distress syndrome requiring prolonged intensive care unit stays). The prognostic impact of measuring viral load on nasopharyngeal swab specimens (by reverse transcriptase polymerase chain reaction [RT‐PCR]) is yet to be elucidated. METHODS: Between March 3 and April 5, 2020, we conducted a retrospective study on a cohort of COVID‐19 patients (mild or severe disease) who were hospitalized after presenting to the emergency department (ED) and had at least one positive nasopharyngeal swab during their hospital stay. We led our study at the University Hospitals of Strasbourg in the Greater East region of France, one of the pandemic's epicenters in Europe. RESULTS: We have collected samples from a cohort of 287 patients with a confirmed diagnosis of COVID‐19 who were included in our study. Nearly half of them (50.5%) presented a mild form of the disease, while the other half (49.5%) presented a severe form, requiring mechanical ventilation. Median (interquartile range) viral load on the initial upper respiratory swab at admission was 4.76 (3.29–6.06) log(10) copies/reaction. When comparing survivors and nonsurvivors, this viral load measurement did not differ according to subgroups (p = 0.332). Additionally, we have found that respiratory viral load measurement was predictive of neither in‐hospital mortality (adjusted odds ratio [AOR] = 1.05, 95% confidence interval [CI] = 0.85 to 1.31, p = 0.637) nor disease severity (AOR = 0.88, 95% CI = 0.73 to 1.06, p = 0.167). CONCLUSION: Respiratory viral load measurement on the first nasopharyngeal swab (by RT‐PCR) during initial ED management is neither a predictor of severity nor a predictor of mortality in SARS‐CoV‐2 infection. Host response to this viral infection along with the extent of preexisting comorbidities might be more foretelling of disease severity than the virus itself.

In December 2019, a devastating pandemic caused by a novel coronavirus, SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) started to spread around the world. 1 As of July 1, 2020, this emerging virus has infected more than 10 million people resulting in over 500,000 deaths worldwide. The clinical spectrum of this viral infection is broad. Once infected, the patients are, for a majority, asymptomatic or only slightly symptomatic presenting influenza-like disease. A certain number develops a mild disease and may require hospitalization (viral pneumonia, hypoxemia). A minority suffers from critical complications such as acute respiratory distress syndrome (ARDS) requiring prolonged mechanical support in the intensive care unit (ICU). 2, 3 In such challenging times of crisis, health care systems were overwhelmed. Hence, strategies of rationing medical resources were followed. These enforced vital protocols were guided by extreme clinical anticipation and accurate triage where patients are addressed according to severity and chances of survival. 4 Several recent studies have investigated predictive factors of in-hospital mortality and severity in COVID-19 patients. Light was shed on clinical, biochemical risk factors, and other demographic characteristics such as comorbidities (hypertension, obesity) and age. 5, 6 Moreover, in the context of other emerging coronavirus infections, the measurement of viral load on respiratory specimens has proven to be indicative of active virus replication and was used to assess disease progression and effectiveness of treatment. 7 The pathophysiology of this emerging viral infection is yet to be fully understood. We know so far that an immune response dysfunction and an imbalance in the host response seem to determine disease progression along with the risk of developing critical complications. 8, 9 Sparse studies have focused on initial viral load in respiratory specimens as a marker of critical disease progression. 10 In addition, viral load on nasopharyngeal swabs (by reverse transcriptase polymerase chain reaction [RT-PCR]) appears to be a risk factor for intubation and in-hospital mortality. 11 Thus, viral load could be a useful marker of severe disease and may be used to identify patients eligible for more aggressive treatment or early ICU admission and to characterize populations for future therapeutic studies.

We conducted this study on a cohort of COVID-19 patients (mild or severe disease) who were hospitalized after presenting to the emergency department (ED) at the University Hospitals of Strasbourg (France). Our main outcome was to investigate the viral load in nasopharyngeal swab upon presentation to the ED as a severity and disease progression parameter of SARS-CoV-2 infection.

This monocentric study was conducted in the ED of the University Hospitals of Strasbourg. This medical institution has an inpatient bed base of 2500 and its ED receives and treats about 75,000 patients yearly. It is located in the Greater East region of France, one of the most impacted regions in Europe by the pandemic, with nearly 3500 deaths and more than 12,000 infected patients as of end of June 2020. However, during the pandemic, the ED witnessed a paradoxal 40% decrease in the number of patient visits.

Between March 3 and April 5, 2020, all adult patients hospitalized for COVID-19 were retrospectively included upon admission to the ED of a French teaching hospital. Patients were managed following current guidelines without specific therapeutic intervention. 12 All patients had at least one nasopharyngeal swab where RT-PCR was positive. Patients who had no positive swab during their hospital stay or received outpatient care were excluded. Those who received palliative therapy or limitation of therapeutic effort upon admission to the ED were also excluded from the study.

Upon presentation to the ED, all patients underwent nasopharyngeal swab sampling on which the viral load was measured. Extraction was performed on the eMAG/eSTREAM platform (bioMérieux, Marcy l'Etoile, France) and was followed by amplification on the LightCycler 480 II system (Roche Diagnostics, France). Real-time RT-PCR targeted the polymerase gene using the Flo2 and Flo4 primer and probe sets. 13 Quantification was performed using successive dilutions of the CoV_IP transcript to allow the correspondence between the number of cycles and the viral load in copy/reaction.

We retrospectively sourced the data from patients' electronic medical records and then standardized it in a case report file. The collected data included epidemiologic, clinical, and biochemical details. Date of symptom onset was also recorded. Patients' current treatments and medical history including cardiovascular, diabetes, renal, cancer, and hematologic diseases were collected. Overweight was defined by a body mass index superior to 30 kg/m 2 . Standard biochemical parameters, such as hemoglobin, platelets, C-reactive protein (CRP), total leukocytes, and total lymphocytes, were also gathered.

COVID-19, mortality, nasopharyngeal swabs, severity, viral load

This study was approved by the local ethics committee of the University of Strasbourg in France (reference CE 2020-35). In light of the clinical and epidemiologic context, oral consent for the use of medical data could not be obtained for all patients, but was systematically confirmed by patients' relatives and after the critical stage by patients themselves or their relatives in case of death.

Continuous variables are presented as median (interquartile range

[IQR]) of the distribution and were compared using nonparametric Wilcoxon rank-sum tests. Categorical variables are described as counts and proportions and were compared using Pearson's chisquare tests or Fisher's exact tests depending on theoretical numbers. Missing values were handled using multiple imputations by chained equations. 14,15 Factors associated with death or severity were identified using multivariable logistic regression models. All the variables with clinical relevance or with a p-value of <0.2 in univariable analysis were included in the models. No further variable selection procedures were subsequently carried out. We presented the multivariable model based on clinical expertise. Multicollinearity was assessed by using the variance inflation factor (VIF) and ensuring that no factor had a VIF greater than 2. Goodness of fit for the logistic regression models was assessed by using the Hosmer-Lemeshow test. Results are presented as adjusted odds ratios (AORs) with their 95% confidence intervals (CIs). Receiver operating characteristic (ROC) curve analysis was established to evaluate the predictive performance of viral load on death or severity. Area under the curve (AUC) was computed with its 95% CI. A p-value of <0.05 was considered as statistically significant. All the analyses were performed using R software version 3. 

During the study period, 5421 patients presented to the ED; 1617 patients were suspected of COVID-19 and thus received a nasopharyngeal swab. In fine, a total of 577 COVID-positive F I G U R E 1 Flowchart of the study. Abbreviations: ICU, intensive care unit; RT-PCR, reverse transcriptase polymerase chain reaction patients were hospitalized following their visit to the ED, 154 (26.7%) of whom were in intensive care. We managed to include, after obtaining consent, a total of 287 patients with a confirmed diagnosis of COVID-19 ( Figure 1 ). The majority of these patients were male (65.8%, 95% CI = 60.3% to 71.3%), the median (IQR) age at time of diagnosis was 63 (50-73) years and onethird of them were overweight (36.6%, 95% CI = 31% to 42.2%).

Regarding medical history, over one-third of patients (37%) had high blood pressure and nearly 20% of them had a history of diabetes. Upon admission to the ED, median (IQR) CRP level was 86 (30-166) mg/L and median creatinine level was 68.7 µmol/L. The respiratory viral load on the first nasopharyngeal swab was 4.76 (3.29-6.06) log 10 copies/reaction. Overall patient characteristics are summarized in Table 1 .

Forty-two patients (14.6%) died during their hospitalization.

Nonsurvivors were significantly older (72.5 years vs. 61.4 years, p < 0.001) than the survivors. Medical history did not differ much in the two groups, aside from more frequent history of dialysis in the nonsurvivor group (p = 0.048). At admission to the ED, nonsurvivors presented significantly higher CRP (122 mg/L vs. 74 mg/L, p = 0.007) and creatinine (p = 0.036) compared to survivors. Nonsurvivors were also more likely to present with anemia (p = 0.003) and lymphopenia (p = 0.02) than survivors. Viral load on the initial respiratory nasopharyngeal swab at admission (4.99 log 10 copies/reaction vs. 4.76 log 10 copies/reaction, p = 0.332) did not differ between the two subgroups.

We also studied the initial viral load's prognostic performance in the prediction of mortality. The area under the ROC curve was 54.7% (95% CI = 45.4 to 64%; Figure 2 ).

On multivariable analysis, age over 65 years was a mortality predictor (AOR = 4.70, 95% CI = 1.29 to 17.07, p = 0.019). A previous history of dialysis (AOR = 14.43) and anemia (AOR = 5.14) at baseline was also associated with in-hospital mortality. However, the viral load on the initial nasopharyngeal swab did not appear to be significantly associated with mortality (AOR = 1.05, 95% CI = 0.85 to 1.31, p = 0.637). Results are summarized in Table 2 .

We found that nearly half of our study population, 145 patients (50.5%), presented with a mild form of the disease, while the other half, 142 patients (49.5%), displayed a severe presentation requiring Abbreviations: BMI, body mass index; COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein. Table 3 .

We also studied the initial viral load's prognostic performance in the prediction of disease severity. The area under the ROC curve was 59.3% (95% CI = 52.7 to 65.9%; Figure 3 ). Table 4 .

We studied a cohort of 287 hospitalized patients with a confirmed diagnosis of SARS-CoV-2 infection. Infection diagnosis is usually confirmed by RT-PCR on nasopharyngeal swab on which respiratory viral load measurement is therefore possible, yet not widely used in the management of viral infections. Some authors have suggested that serum viral load correlates with inflammation (IL-6) and clinical severity. 16 We have analyzed the initial viral loads on nasopharyngeal swabs collected at admission to the ED during the COVID-19

pandemic. This allowed us to demonstrate that respiratory viral load was neither a risk predictor of infection severity nor mortality. To the best of our knowledge, our study is one of the first of this type, comparing viral load measurement in a population of COVID-19 hospitalized patients. of preexisting renal failure. 20 High CRP (>100 mg/dL), anemia (<10 g/dL), and lymphopenia (<1500/µL) were predictive of clinical severity (admission to ICU). 21 Our results support the theory that host immune response to the virus displays a great influence on the evolution and severity of the disease. This response to infection seems to be more related to the extent of the hosts' chronic comorbid medical conditions and their impaired physiological reserve than to the level of viral load itself; severity of disease progression hence seems to be more determined by the hosts' characteristics than the quantifiable parts of the virus.

Thus, potential future therapeutic strategies should consider approaching and targeting this disproportionate and dysregulated host response to viral infection. 27 The pathophysiology of this SARS-CoV-2-related disease is not yet well established. 28 However, the virus appears to initially target respiratory epithelial cells, endothelial cells, and lung macrophages, resulting in a true local host cell response to the infection. 9 The clinical severity of the disease (leading to ARDS) manifests, at times, brutally at the beginning of the infection and, at other times, more progressively 6 to 10 days after the onset of symptoms. 29 This biphasic evolution is underlined by a cytokine storm, which suggests a dysregulated inflammatory host response to an imbalance between pro-and anti-inflammatory mediators. 30 The systemic inflammatory response syndrome is particularly responsible for activating blood coagulation and, thus, increasing risks of thrombosis in patients with severe SARS-CoV-2 infection. 31 These also lead to the recruitment and accumulation of leukocytes in tissues causing ARDS. Although these data shed light on the role and impact of immunologic and molecular physiopathology, further mechanisms remain to be investigated at this stage. 32 As in bacterial sepsis, viral sepsis is also the result of a dysregulated host immune response to infection. 33 

Our study presents some limitations like its retrospective nature and the relatively small sample size. The results of the multivariable model for in-hospital mortality should be cautiously interpreted due to a low number of events per variable. Furthermore, our study was led in one center (Strasbourg's University Hospitals), yet it should be noted that it was conducted at the pandemic's epicenter in France. We did not monitor temporal changes in viral load over time (e.g., rate of viral load expansion or viral load clearance); this variation could be assessed as a marker of severity. In addition, viral load could be relevant to other aspects of COVID-19 like transmissibility and other studies will be needed to address those questions. Finally, given the workload and pressure submerging our health care systems during the pandemic, the overall parameters of the hospital stay could not be exhaustively collected and detailed.

In conclusion, respiratory viral load measurement on the first nasopharyngeal swab (reverse transcriptase polymerase chain reaction) during initial ED management was neither a predictor of severity nor a predictor of 

A novel coronavirus from patients with pneumonia in China

Severe covid-19

Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area

The toughest triage -allocating ventilators in a pandemic

Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series

Development and validation of a clinical risk score to predict the occurrence of critical illness in hospitalized patients with COVID-19

Respiratory tract samples, viral load, and genome fraction yield in patients with Middle East respiratory syndrome

The trinity of COVID-19: immunity, inflammation and intervention

Imbalanced host response to SARS-CoV-2 drives development of COVID-19

Viral load dynamics and disease severity in patients infected with SARS-CoV-2 in Zhejiang province, China

Impact of SARS-CoV-2 viral load on risk of intubation and mortality among hospitalized patients with coronavirus disease 2019

Surviving Sepsis Campaign: guidelines on the management of critically ill adults with coronavirus disease 2019 (COVID-19)

In-depth virological assessment of kidney transplant recipients with COVID-19

mice: multivariate imputation by chained equations in R

Missing data and multiple imputation in clinical epidemiological research

Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients

Epidemiological and clinical predictors of COVID-19

Clinical characteristics and morbidity associated with coronavirus disease 2019 in a series of patients in metropolitan Detroit

Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy

Acute kidney injury in critically ill patients with COVID-19

Changes of hematological and immunological parameters in COVID-19 patients

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Nasopharyngeal viral load predicts hypoxemia and disease outcome in admitted COVID-19 patients

SARS-CoV-2 viral load predicts COVID-19 mortality

Temporal dynamics in viral shedding and transmissibility of COVID-19

Diagnostic performance of CT and reverse transcriptase-polymerase chain reaction for coronavirus disease 2019: a meta-analysis

Emerging pharmacological therapies for ARDS: COVID-19 and beyond

The trinity of COVID-19: immunity, inflammation and intervention

Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia

Cytokine storm syndrome in coronavirus disease 2019: a narrative review

Prothrombotic phenotype in COVID-19 severe patients

Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients

The third international consensus definitions for sepsis and septic shock

The immunopathogenesis of sepsis in elderly patients

How to cite this article

SARS-CoV-2 viral load in nasopharyngeal swabs in the emergency department does not predict COVID-19 severity and mortality

mortality in SARS-CoV-2 infection. Host response to viral infection and the extent of preexisting comorbidities might be more determinant of disease severity and critical progression than the virus load itself.

The authors have no potential conflicts to disclose.

All authors contributed to the design of the study and analysis of data, drafting the paper, and approving the final version.

https://orcid.org/0000-0001-9141-6439Ferhat Meziani https://orcid.org/0000-0001-7190-3109